Analyst Reco. Immunome, Inc.

Equities

IMNM

US45257U1088

Market Closed - Nasdaq Other stock markets 21:00:00 14/05/2024 BST			5-day change	1st Jan Change
14.72 ^USD	-5.70%		-3.98%	+37.57%

05-14	Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	CI
05-14	Certain Warrants of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Starts Immunome With Overweight Rating, $24 Price Target	04-30	MT
Guggenheim Starts Immunome With Buy Rating, $35 Price Target	04-15	MT
Wedbush Adjusts Immunome's Price Target to $33 From $27, Maintains Outperform Rating	04-01	MT
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating	02-07	MT
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating	01-23	MT
Immunome Shares Rise After Wedbush Starts Coverage With outperform Rating	12-19	MT
Wedbush Starts Immunome With Outperform Rating, $12 Price Target; Has Positive View for Early-Stage Pipeline of Targeted Cancer Therapies	12-19	MT
Chardan Cuts Price Target on Immunome to $8 From $9, Maintains Buy Rating	17/03/23	MT
Cantor Fitzgerald Initiates Immunome's Coverage With Overweight Rating, Sets Price Target at $8	27/09/22	MT
Chardan Adjusts Immunome's Price Target to $9 From $16, Citing IMM-BCP-01 Launch Expectations, Stock Dilution From Future Capital Raises; Buy Rating Kept	13/05/22	MT
Cantor Fitzgerald Starts Immunome at Overweight with $35 Price Target	29/10/21	MT
IMMUNOME : Chardan Adjusts Price Target on Immunome to $21 From $18 on Q2 Update, Maintains Buy Rating	20/08/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer